The association between rs1260326 with the risk of NAFLD and the mediation effect of triglyceride on NAFLD in the elderly Chinese Han population

Fan Yuan1,*, Zhan Gu2,*, Yan Bi1, Ruixue Yuan1, Weibo Niu1, Decheng Ren1, Lei Zhang2, Guang He1, Bao-Cheng Liu2

1Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Shanghai Jiao Tong University, Shanghai 200030, China
2Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
*Equal contribution

Correspondence to: Guang He, Bao-Cheng Liu; email: heguang@sjtu.edu.cn, baochliu@shutcm.edu.cn
Keywords: NAFLD, GCKR, genetic association, triglyceride, mediation analysis
Received: August 17, 2021 Accepted: January 17, 2022 Published: March 25, 2022

ABSTRACT

Background: Accumulated studies have pointed out the striking association between variants in or near APOC3, GCKR, PNPLA3, and nonalcoholic fatty liver disease (NAFLD) at various ages from multiple ethnic groups. This association remained unclear in the Chinese Han elderly population, and whether this relationship correlated to any clinical parameters was also unclear.

Objectives: This study aims to decipher the complex relevance between gene polymorphisms, clinical parameters, and NAFLD by association study and mediation analysis.

Methods: Eight SNPs (rs2854116, rs2854117, rs780093, rs780094, rs1260362, rs738409, rs2294918, and rs2281135) within APOC3, GCKR, and PNPLA3 were genotyped using the MassARRAY® platform in a large Chinese Han sample comprising of 733 elderly NAFLD patients and 824 age- and ethnic-matched controls. Association and mediation analysis were employed by R.

Results: The genotypic frequencies of rs1260326 and rs780094 were significantly different between NAFLD and control (rs1260326: P=0.004, Pcorr=0.020, OR [95%CI]= 0.69 [0.54-0.89]; rs780094: P=0.005, Pcorr=0.025, OR [95%CI]= 0.70 [0.55-0.90]). Particularly, an increased triglyceride level was observed in carriers of rs1260326 T allele (1.94±1.19 mmol/L) compared with non-carriers (1.73±1.05 mmol/L). No significant results were observed in rs780094. Notably, triglyceride levels had considerably indirect impacts on association between NAFLD and rs1260326 (β =0.01, 95% CI: 0.01–0.02), indicating that 12.7% of the association of NAFLD with rs1260326 was mediated by triglyceride levels.

Conclusions: Our results identified a prominent relationship between GCKR rs1260326 and NAFLD, and highlighted the mediated effect of triglyceride levels on the that association in the Chinese Han elderly.

INTRODUCTION

Nonalcoholic fatty liver disease (NAFLD) is defined by lipid deposition exceeding more than 5% of hepatocytes and/or more than 5.6% hepatocellular fat content per weight unit of liver without significant alcohol consumption and other causes of fatty liver [1, 2]. It has been the most prominent cause of chronic liver disease worldwide with the global prevalence being around 25% [3].
NAFLD is considered to possess a complex trait resulting from environmental exposures and multiple susceptible genes. According to available data, the heritability was estimated to range from 20% to 70% [4]. The exact pathogenesis of NAFLD is not clarified completely, but increasing evidence supported the role of single nucleotide polymorphism (SNP) in the risk and development of NAFLD, especially SNPs within those genes associated with lipid handling and oxidative stress, such as the patatin-like phospholipase domain containing protein 3 (PNPLA3), glucokinase regulatory protein gene (GCKR), and apolipoprotein C3 (APOC3) gene [5, 6].

GCKR was previously well-described to be involved in the development of NAFLD in children and adolescents [7]. Some genome-wide association studied (GWAS) and meta-analyses showed that GCKR rs780094, rs780094, and rs1260326 were closely related to the risk of NAFLD in Japanese [8], Iran [9], Danish [10], and Swedish [11] populations. In China, it is reported that GCKR polymorphism was associated with NAFLD in the Uyghur population [12]. However, in the Han population, especially in the elderly population, more studies are necessary to be carried out. Notably, the researchers found that rs780093 was associated with triglyceride (TG) levels in Europeans, which is a risk factor for NAFLD [13].

Meanwhile, PNPLA3 SNPs were also reported to be relevant to lower NAFLD risk in a population comprising Hispanic, African American, and European American individuals [14]. PNPLA3 rs738409 and rs2294918 influence the hepatic fat content in India by an exome-wide approach [15, 16]. Another PNPLA3 SNPs, rs2281135, showed a significant association with the NAFLD in a Korean [17].

To our interest, the relationship between NAFLD and APOC3 promoter region SNPs rs2854117 and rs2854116 is controversial in different studies. It has been proposed that rs2854116 and rs2854117 were associated with NAFLD in lean individuals of South Asian descent [18]. On the contrary, Federica et al. did not identify any significant association between these two APOC3 SNPs and NAFLD in Southern Europeans [19].

Overall, the association between APOC3, GCKR, PNPLA3 gene and NAFLD in the elderly Chinese Han population remains unclear or controversial. We carried on our study to explore the relationship between several SNPs within these three genes, NAFLD and clinical parameters in the elderly Han Chinese population to decipher the complex relationship between gene polymorphisms, clinical parameters, and the risk of NAFLD.

MATERIALS AND METHODS

Subjects

This study was conducted during 2015 and 2016 in Shanghai, China. Initially, 765 NAFLD patients and 860 ethnic- and age-matched healthy controls were recruited in this study. NAFLD was defined by evidence of hepatic steatosis on B-mode Philips ClearVue 550 ultrasound system with a 3.5MHz C5-1 broadband curved array transducer (Philips Medical System, Bothell, WA, USA), and evaluated by two expert and board-certified radiologists. NAFLD was diagnosed according to the guidelines for managing NAFLD of the Chinese Medical Association in 2010 [20]. All the subjects should meet the following standards: 1) all above the age of 60; 2) permanent residents of the Zhangjiang area in Pudong district, Shanghai.;3) no alcohol abuse (< 140g/week for male and < 70g/week for female); 4) Chinese Han population with no blood relation to each other; 5) free of drug-induced liver disease or autoimmune liver disease; 6) no carriers of hepatitis B or C. The Ethics Committee in Shanghai University of Traditional Chinese Medicine approved this study. Informed consents were obtained from all subjects.

Clinical parameters

The baseline information such as age, gender, alcohol consumption, current smoking, and medical history were collected by questionnaire. The height and body weight were measured by an electronic measurement instrument (Shengyuan, Zhengzhou, China). Body mass index (BMI) was calculated according to the formula body weight/height^2 (kg/m^2). Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) were measured by electronic sphygmomanometers (Biospace, Cheonan, South Korea).

Blood samples were obtained from subjects after an overnight fasting period. Fasting plasma glucose (FPG), total cholesterol (TC), TG, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), alanine transaminase (ALT), alkaline phosphatase (ALP), aspartate transaminase (AST), and gamma-glutamyl transferase (GGT) were measured using an automatic biochemistry analyzer (Hitachi, Tokyo, Japan).

Genotyping

Genomic DNA was extracted from venous blood leukocytes by the standard phenol-chloroform method. Totally, eight SNPs were selected from the literature and the National Center for Biotechnology Information
dbSNP database (http://www.ncbi.nlm.nih.gov/SNP) for Genotyping by a matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometer using the MassARRAY® Analyzer 4 platform (Sequenom, CA, USA). The SNPs information included in the final analysis is listed in Table 1. The minor allele frequency (MAF) of SNPs in our present study was comparable to that in East Asian population reported in the 1000 Genomes Project [21]. In order to ensure the reliability of genotyping quality, quality control was carried out at both an individual level and a SNP level [22]. At the individual level, subjects with incomplete information were excluded. In addition, individuals with a call rate of less than 0.8 were also excluded. SNPs that violated Hardy-Weinberg equilibrium (HWE<0.05) were removed at the SNP level. Moreover, no template controls (>1%) were called blind to their status in the genotyping process and each SNP was re-genotyped in at least 5% random DNA samples.

Statistical analysis

Continuous variables like age and BMI were presented as the mean ± standard error and analyzed by t-test. Categorical variables like gender were describe as a percentage and analyzed by chi-square test. The HWE, allelic and genotypic distribution was examined using an R package called SNPassoc (https://cran.r-project.org). For pairwise linkage disequilibrium (LD) analysis, Haploview 4.2 (Broad Institute, Cambridge, MA, USA) was carried out. To analyze the eight SNPs, we perform Bonferroni correction (Pcorr = P-value*8) to prevent inflation of the type I error. Mediation models were established to explore whether TG mediated the association between SNP and NAFLD by an R-package called mediation. P-values were two tailed and the threshold of statistical difference was set at Pcorr <0.05. Furthermore, the illustration was created with BioRender.com (https://biorender.com).

RESULTS

Demographics of study subjects

1625 subjects were initially enrolled in this study. 51 patients were removed due to the absence of blood samples, personal information, or failure of genotyping. 1557 individuals were in the final analysis consisting of 733 NAFLD patients and 824 healthy controls. Details about age, gender, BMI, and clinical characteristics (Diabetes, Hypertension, Hypertriglyceridemia, Hypercholesteremia and Hyperuricemia) among NAFLD patients and control were shown in Table 2. There were no significant differences in age, gender, the percentage of hypercholesteremia and hyperuricemia between NAFLD and control groups. Nevertheless, BMI was significantly higher in NAFLD (NAFLD: 26.11 ± 3.269 kg/m² VS. Control: 24.28 ± 3.474 kg/m²; P < 0.05). The percentages of Diabetes (NAFLD: 25.10% VS. Control: 20.63%; P = 0.036), hypertension (NAFLD: 63.44% VS. Control: 51.21%; P = <0.001), and hypertriglyceridemia (NAFLD: 55.14% VS. Control: 40.86%; P = <0.001) were also remarkably higher in NAFLD.

Genetic association between SNPs and NAFLD

As is described in Table 3, the allelic distributions of all SNPs were in HWE (all P>0.05). The frequency of C allele of GCKR rs780094 was significantly lower in NAFLD than in control (OR= 0.867, 95%CI= 0.75-0.99; P= 0.048). However, this result did not survive after Bonferroni correction (Pcorr= 0.384).

Five different genetic models (Codominant, Dominant, Recessive, Overdominant, and Log-additive) of each SNP were tested to assess their association with NAFLD further. As shown in Figure 1, the recessive model of rs1260326 was still statistically significant after Bonferroni correction. Likewise, the significant result of rs780094 survived in recessive model after Bonferroni correction. No other SNPs obtained significant differences in any genetic model.

Association of GCKR rs1260326 variant with NAFLD and clinical parameters

The detailed genotypic distributions of rs1260326 are listed in Table 4. A significantly different result was observed in the recessive model after Bonferroni correction. The rs1260326 CC genotype was remarkably related to decreased risk of NAFLD (OR=0.69; 95%CI=0.54-0.89; Pcorr =0.020). In addition, the association remained significant after adjusting for age, gender and BMI (OR=0.70; 95%CI=0.54-0.91; Pcorr =0.035). These results suggested that GCKR rs1260326 polymorphism is associated with the risk of NAFLD in Chinese Han elderly population.

The associations between the GCKR rs1260326 variant and the hepatic enzyme, lipid, blood pressure, and FBG levels are shown in Figure 2. An increased TG level was observed in carriers of rs1260326 T allele (1.94±1.19 mmol/L) compared with non-carriers (1.73±1.05 mmol/L). However, no marked difference of other clinical parameters was observed between the carriers and non-carriers of the rs1260326 T allele (p > 0.05).
Table 1. The SNPs analyzed in this study.

| SNP     | Gene   | Location   | Alleles | Chromosome position | MAF_G | MAF_E | MAF_P |
|---------|--------|------------|---------|---------------------|-------|-------|-------|
| rs2854116 | APOC3  | Upstream   | C>T     | 11:116829453        | 0.452 | 0.470 | 0.435 |
| rs2854117 | APOC3  | Upstream   | T>A / T>C | 11:116829426   | 0.499 | 0.474 | 0.432 |
| rs1260326 | GCKR   | Missense   | T>C / T>G | 2:27508073       | 0.293 | 0.481 | 0.453 |
| rs780094  | GCKR   | Intron     | T>C     | 2:27518370         | 0.302 | 0.476 | 0.462 |
| rs780093  | GCKR   | Intron     | T>C     | 2:27519736         | 0.292 | 0.480 | 0.467 |
| rs738409  | PNPLA3 | Missense   | C>G / C>T | 22:43928847     | 0.293 | 0.481 | 0.453 |
| rs2294918 | PNPLA3 | Intron     | T>C     | 22:43946236       | 0.302 | 0.476 | 0.462 |
| rs738409  | PNPLA3 | Intron     | G>A / G>C | 22:43936690    | 0.257 | 0.364 | 0.354 |

1The SNP Chromosome positions are based on the NCBI human genome build GRCh38.p12.
MAF_G, minor allele frequency in global; MAF_E, minor allele frequency in East Asian; MAF_P, minor allele frequency in present study.
Global and East Asian allele frequencies information was collected from 1000 genomes project [21].

Table 2. Demographic and clinical characteristics of subjects.

|                     | Control (824) | NAFLD (733) | P     |
|---------------------|---------------|-------------|-------|
| Age (years)         | 71.66 ± 6.394 | 71.47 ± 6.682 | 0.560 |
| BMI (kg/m^2)        | 24.28 ± 3.474 | 26.11 ± 3.269 | <0.001* |
| Gender (male, %)    | 42.48         | 40.38       | 0.403 |
| Diabetes (%)        | 20.63         | 25.10       | 0.036* |
| Hypertension (%)    | 51.21         | 63.44       | <0.001* |
| Hypertriglyceridemia (%) | 40.86     | 55.14       | <0.001* |
| Hypercholesteremia (%) | 26.44       | 25.68       | 0.773 |
| Hyperuricemia (%)   | 16.23         | 17.57       | 0.521 |

BMI, body mass index; *statistically significant.

Table 3. Allelic distribution of SNPs between NAFLD and control.

| SNP       | Allele| T/C | MAF   | HWE | chi2 | OR [95% CI] | P     | Pcorr |
|-----------|-------|-----|-------|-----|------|-------------|-------|-------|
| rs2854116 | NAFLD | 826/640 | 0.436 | 0.69 | 0.023 | 1.011 | 0.879 | >0.999 |
| control   |       | 933/715 | 0.433 |       |       | [0.87-1.16] |       |       |
| rs2854117 | NAFLD | 825/641 | 0.437 | 0.088 | 0.319 | 1.041 | 0.571 | >0.999 |
| control   |       | 944/704 | 0.427 |       |       | [0.90-1.20] |       |       |
| rs1260326 | NAFLD | 829/637 | 0.434 | 0.759 | 3.735 | 0.869 | 0.053 | 0.424 |
| control   |       | 875/773 | 0.469 |       |       | [0.75-1.00] |       |       |
| rs780094  | NAFLD | 816/650 | 0.443 | 0.541 | 3.906 | 0.867 | 0.048* | 0.384 |
| control   |       | 859/789 | 0.478 |       |       | [0.75-0.99] |       |       |
| rs780093  | NAFLD | 808/659 | 0.448 | 0.541 | 3.639 | 0.871 | 0.056 | 0.448 |
| control   |       | 852/796 | 0.485 |       |       | [0.75-1.00] |       |       |
| rs738409  | NAFLD | 952/514 | 0.35  | 0.655 | 0.175 | 1.032 | 0.674 | >0.999 |
| control   |       | 1082/566 | 0.343 |       |       | [0.89-1.19] |       |       |
| SNP     | Condition   | Case     | Control | OR    | 95% CI  | Pcorr | Pcorr Value |
|---------|-------------|----------|---------|-------|---------|-------|-------------|
| rs2294918 | NAFLD      | 1191/271 | 1308/334 | 0.185 | 0.145   | 1.605 | 0.891       | 0.205 | >0.999     |
| control |             |          |         |       |         |       |             |
|          | G/A        |          |         |       | [0.74-1.06] |     |             |
| rs2281135 | NAFLD      | 943/523  | 1069/579 | 0.356 | 0.868   | 0.099 | 1.023       | 0.752 | >0.999     |
| control |             |          |         |       | [0.88-1.18] |     |             |

MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium; OR, odds ratio; CI, confidence interval; Pcorr, P value after Bonferroni correction; *statistically significant.

Figure 1. Genotype frequency analysis in five genetic models. The genotype frequencies of rs1260326 and rs780094 were statistically different in the recessive model after Bonferroni correction.
Association of GCKR rs780094 variant with NAFLD and clinical parameters

The detailed genotypic distributions of rs780094 were listed in Table 5. A significantly different result was observed in the recessive model after Bonferroni correction. rs780094 CC genotype was remarkably related to decreased risk of NAFLD (OR=0.70; 95% CI=0.55-0.90; Pcorr =0.025). In addition, the association remained significant after adjusting for age, sex and BMI (OR=0.70; 95% CI=0.54-0.90; Pcorr =0.030). However, we did not find any differences in clinical parameters between rs780094 CC and CT+TT genotype (data is not shown here).

Mediated effect of TG on the association of rs1260326 and NAFLD

As reported above, the rs1260326 polymorphism was associated with TG level and NAFLD risk. Also, we found that the TG level was correlated with NAFLD, suggesting that the mechanism underlines the association between rs1260326 and NAFLD was possibly mediated by TG level. We conducted mediation analysis to explore whether TG mediated the association between rs1260326 and NAFLD. As shown in Figure 3, mediation analysis indicated that rs1260326 had a significant direct effect on NAFLD incidence (β =0.74, 95% CI: 0.02–0.13, P<0.001), and TG mediated the indirect effect on NAFLD incidence by 12.7% (β =0.01, 95% CI: 0.01–0.02).

Haplotype analysis

We identified rs1260326-rs780094-rs780093 as a strong LD block in the GCKR gene with Haploview analysis (Figure 4).

DISCUSSION

To the best of our knowledge, this is the first time investigating the relationship between APOC3, GCKR, PNPLA3 gene polymorphisms with NAFLD and clinical parameters in the Chinese Han elderly. Here, we analyzed two APOC3 SNPs (rs2854116 and rs2854117), three GCKR SNPs (rs780093, rs780094, and rs1260326), and three PNPLA3 SNPs (rs738409, rs2294918, and rs2281135) in 1557 Chinese Han elderly subjects. We found that rs780094 and rs1260326 were significantly associated with NAFLD in the elderly Chinese Han population. Of note, rs1260326 T allele was related to higher TG levels, and about 12.7% of the rs1260326 effect on NAFLD was mediated through TG levels.

The glucokinase regulatory protein, translated by GCKR gene, is an inhibitor of glucokinase (GCK) activity which is the principal hexokinase in the liver. GCK functioned as a glucose sensor to regulate glucose metabolism and has been reported to be closely related to hepatic insulin sensitivity, playing a vital role in the development of NAFLD [23–25]. Moreover, GCKR-deficient mice supported that the disruption of GCKR regulation could cause glycemic control impairment [26]. N. Santoro et al. found that GCKR gene variant was associated with NAFLD in children and adolescents [27]. However, few studies were focusing on the elderly. The rs780094 SNP within GCKR gene was associated with liver fat accumulation, increased triglyceride concentrations, reduced insulin levels, and reduced risk of type 2 diabetes [28, 29]. Inconsistent results have been reported about the effects of GCKR polymorphisms on the risk of NAFLD, probably due to the ethnic differences among the NAFLD patients studied [30–32]. We confirmed the result reported by
Figure 2. Levels of clinical parameters between rs1260326 CC and genotypes. TG level in carriers of rs1260326 T allele (1.94±1.19 mmol/L) was significantly higher than non-carriers (1.73±1.05 mmol/L). However, no marked difference of other clinical parameters was observed between the carriers and non-carriers of rs1260326 T allele (p > 0.05). ALP, alanine Phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; FPG, fasting plasma glucose; TC, total cholesterol; TG, triglyceride; SBP, systolic blood pressure; DBP, diastolic blood pressure; GGT, glutamyl transpeptidase; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; * p < 0.05. All data are represented as mean ± s.e.m.
Table 5. GCKR rs780094 genotype distributions in five genetic models.

| Model                | Control (%) | NAFLD (%) | OR  | 95% CI       | P     | Pcorr | OR1 | 95% CI1 | P2 | Pcorr,1 |
|----------------------|-------------|-----------|-----|--------------|-------|-------|-----|---------|----|---------|
| Codominant           | T/T         | 27.9      | 29.2| 1            | 0.018 | 0.09  | 1   | 0.022*  | >0.999 |         |
|                      | T/C         | 48.4      | 52.9| 1.05         | [0.83-1.32] | 0.97  | [0.77-1.24] |       |
|                      | C/C         | 23.7      | 17.9| 0.72         | [0.54-0.96] | 0.69  | [0.51-0.93] |       |
| Dominant             | T/T         | 27.9      | 29.2| 1            | 0.576 | >0.999 | 1   | 0.273   | >0.999 |         |
|                      | T/C+C/C     | 72.1      | 70.8| 0.94         | [0.75-1.17] | 0.88  | [0.71-1.11] |       |
|                      | T/T+T/C     | 76.3      | 82.1| 1            | 0.005 | 0.025* | 1   | 0.006*  | 0.030* |         |
| Recessive            | C/C         | 23.7      | 17.9| 0.7          | [0.55-0.90] | 0.7   | [0.54-0.90] |       |
| Overdominant         | T/T+C/C     | 52.9      | 47.1| 1            | 0.076 | 0.38  | 1   | 0.211   | >0.999 |         |
|                      | T/C         | 48.4      | 52.9| 1.2          | [0.98-1.46] | 1.14  | [0.54-0.90] |       |
| log-Additive         | 0,1,2       | 52.9      | 47.1| 0.86         | [0.75-1.00] | 0.046 | 0.23  | 0.84 | [0.72-0.97] | 0.021* | >0.999 |

In additive genetic model, genotypes were coded as 0, 1, or 2 according to the number of minor allele for a specific individual. P value after Bonferroni correction; *statistically significant.

1Associations were tested using logistic regression with adjustment for age, gender, and BMI.

Figure 3. Mediation of TG on the association between rs1260326 and NAFLD. Zero was not included in 95% confidence intervals representing statistical significance. TG, triglyceride; NAFLD, non-alcoholic fatty liver disease.

Figure 4. Linkage disequilibrium plot between SNPs. The number in each square is r²*100 between two SNPs. As shown in the picture above rs1260326-rs780094-rs780093 was identified as a strong block with r²>0.8.
Yang et al. with a larger sample size and older population [32].

Nonsynonymous rs1260326 SNP (C/T, P446L substitution) was identified as a strong signal for total triglycerides concentrations [33]. A study on Caucasian, American, and Iceland populations indicated that variant in rs1260326 may cause GCKR inhibitory function to defect, leading to increased glucokinase activity and hepatic glucose uptake [7]. Additionally, the rs780094 polymorphism was related to elevated type 2 diabetes risk, which may indirectly influence the risk of developing NAFLD [34]. Triglyceride levels had considerably indirect impacts on association between NAFLD and rs1260326.

Our study is the first one to investigate the modulation of the association between rs1260326 and NAFLD in the elderly Chinese Han population by TG concentration. A recent work genotyped five GCKR SNPs and found they were associated with increased TG levels, in which rs1260326 was included [35]. Several molecular mechanisms can explain our findings - they were based on increased glucose uptake associated with GCKR SNP. Firstly, the GCKR rs1260326 T allele was associated with increased TG concentration. Furthermore, a meta-analysis in the European population confirmed this association between rs1260326 T allele and higher serum TG level [36]. Consistently, our present study also revealed the higher TG concentration in carriers of the rs1260326 T allele. In a cross-sectional study, TG/HDL-C was independently related to NAFLD [37].

The mediation statistical model enables researchers to infer why or how the two variables are related, rather than just determining whether the results occur. NAFLD is considered to possess a complex trait resulting from environmental exposures and multiple susceptible genes. Our study is the first research to explore the correlation and causal mediation between TG level and NAFLD in Chinese elderly group even though the mediation effect in our study is not as high as that in Nichols, P. H. et al. result - the mediated effect of TSH on NAFLD was 16.0% [38]. Our mediation analysis showed that TG played a partial mediating role in the relationship between rs1260326 and NAFLD. Our findings provide evidence for the mechanistic role of increased TG levels in the association between rs1260326 and NAFLD.

In our study, the diagnosis method of NAFLD is an alternative to histological diagnosis, as the latter is difficult to obtain and invasiveness. The last but not least, a meta-analysis proved that ultrasound is a reliable and accurate method for detecting moderate to severe fatty liver disease, with non-invasive, low cost, high safety, and good availability [39]. In general, despite the limitations of insufficient SNP coverage in candidate genes and not generalized to the entire population, further genetic studies are needed to evaluate further or confirm the role of GCKR gene in NAFLD.

CONCLUSIONS

In summary, our results demonstrated that the GCKR SNPs rs780094 and rs1260326 might be associated with NAFLD in the elderly Chinese Han. Besides, the rs1260326 T allele was related to higher TG concentration. Of note, TG concentration has partly an indirect effect on the observed association between the GCKR rs1260326 SNP and NAFLD. Our finding provided a reference for future studies on the GCKR in predicting the NAFLD risk.

AUTHOR CONTRIBUTIONS

G.H: Guarantor of integrity of entire study. G.H. and B.L.: Conception and design of the study. L.Z., D.R and W.N.: The sample collection. Y.B. and R.Y: Data acquisition. F.Y. and Z.G.: F.Y. and Z.G.: Experimental studies and Data analysis. F.Y.: Drafting the manuscript. G.H. and B.L.: Manuscript revision. We appreciate the contribution of the members participating in this study.

CONFLICTS OF INTEREST

The author reports no conflicts of interest in this work.

FUNDING

This study was supported by the National Natural Science Foundation of China (No: 81620108030, No: 81603411, No: 81573814), the National Key Research and Development Program (2016YFC0906400, 2016YFC1307000, 2016YFC0905000), the National Nature Science Foundation of China (81421061, 81361120389), and the Shanghai Key Laboratory of Psychotic Disorders (13dz2260500), the National Nature Science Foundation of China (81121001, 31171237, 81421061, 81571503, 81300556), the Shanghai Municipal Commission of Science and Technology Program (99DJ1400601), the Shanghai Leading Academic Discipline Project (B205), Overseas students science and technology activities project merit funding.

REFERENCES

1. European Association for the Study of the Liver (EASL), and European Association for the Study of Diabetes (EASD), and European Association for the Study of
2. Nascimbeni F, Pais R, Bellantoni S, Day CP, Ratziu V, Loria P, Lonardo A. From NAFLD in clinical practice to answers from guidelines. J Hepatol. 2013; 59:859–71. 
https://doi.org/10.1016/j.jhep.2013.05.044 PMID: 23751754

3. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018; 15:11–20. 
https://doi.org/10.1038/nrgastro.2017.109 PMID: 28930295

4. Soookoian S, Pirola CJ. Genetic predisposition in nonalcoholic fatty liver disease. Clin Mol Hepatol. 2017; 23:1–12. 
https://doi.org/10.3350/cmh.2016.0109 PMID: 28268262

5. Verrijken A, Beckers S, Francque S, Hilden H, Caron S, Zegers D, Ruppert M, Hubens G, Van Marck E, Michielsen P, Staels B, Taskinen MR, Van Hul W, Van Gaal L. A gene variant of PNPLA3, but not of APOC3, is associated with histological parameters of NAFLD in an obese population. Obesity (Silver Spring). 2013; 21:2138–45. 
https://doi.org/10.1002/oby.20366 PMID: 23512881

6. Li MR, Zhang SH, Chao K, Liao XH, Yao JY, Chen MH, Zhong BH. Apolipoprotein C3 (-455T>C) polymorphism confers susceptibility to nonalcoholic fatty liver disease in the Southern Han Chinese population. World J Gastroenterol. 2014; 20:14010–7. 
https://doi.org/10.3748/wjg.v20.i38.14010 PMID: 25320562

7. Gao H, Liu S, Zhao Z, Yu X, Liu Q, Xin Y, Xuan S. Association of GCKR Gene Polymorphisms with the Risk of Nonalcoholic Fatty Liver Disease and Coronary Artery Disease in a Chinese Northern Han Population. J Clin Transl Hepatol. 2019; 7:297–303. 
https://doi.org/10.14218/JCTH.2019.00030 PMID: 31915598

8. Zain SM, Mohamed Z, Mohamed R. Common variant in the glucokinase regulatory gene rs780094 and risk of nonalcoholic fatty liver disease: a meta-analysis. J Gastroenterol Hepatol. 2015; 30:21–7. 
https://doi.org/10.1111/jgh.12714 PMID: 25167786

9. Mohammadi S, Farajnia S, Shadmand M, Mohseni F, Baghban R. Association of rs780094 polymorphism of glucokinase regulatory gene with non-alcoholic fatty liver disease. BMC Res Notes. 2020; 13:26. 
https://doi.org/10.1186/s13104-020-4891-y PMID: 31924263

10. Sparsø T, Andersen G, Nielsen T, Burgdorf KS, Gjesing AP, Nielsen AL, Albrechtsen A, Rasmussen SS, Jørgensen T, Borch-Johnsen K, Sandbaek A, Lauritzen T, Madsbad S, et al. The GCKR rs780094 polymorphism is associated with elevated fasting serum triacylglycerol, reduced fasting and OGTT-related insulinaemia, and reduced risk of type 2 diabetes. Diabetologia. 2008; 51:70–5. 
https://doi.org/10.1007/s00125-007-0865-z PMID: 18008060

11. Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H, Roix JJ, Kathiresan S, Hirschhorn JN, Daly MJ, Hughes TE, Groop L, Altshuler D, et al, and Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science. 2007; 316:1331–6. 
https://doi.org/10.1126/science.1142358 PMID: 17463246

12. Cai W, Weng DH, Yan P, Lin YT, Dong ZH, Mailamuguli, Yao H. Genetic polymorphisms associated with nonalcoholic fatty liver disease in Uyghur population: a case-control study and meta-analysis. Lipids Health Dis. 2019; 18:14. 
https://doi.org/10.1186/s12944-018-0877-3 PMID: 30646922

13. Kraja AT, Vaidya D, Pankow JS, Goodarzi MO, Assimes TL, Kullo IJ, Sovio U, Mathias RA, Sun YV, Franceschini N, Absher D, Li G, Zhang Q, et al. A bivariate genome-wide approach to metabolic syndrome: STAMPEED consortium. Diabetes. 2011; 60:1329–39. 
https://doi.org/10.2337/db10-1011 PMID: 21386085

14. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008; 40:1461–5. 
https://doi.org/10.1038/ng.257 PMID: 18820647

15. Chatterjee A, Basu A, Das K, Chowdhury A, Basu P. Exome-wide scan identifies significant association of rs4788084 in IL27 promoter with increase in hepatic fat content among Indians. Gene. 2021; 775:145431. 
https://doi.org/10.1016/j.gene.2021.145431 PMID: 3344683

16. Donati B, Motta BM, Pingitore P, Meroni M, Pietrelli A, Alisi A, Petta S, Xing C, Dongiovanni P, del Monaco B, Rametta R, Mancina RM, Badiali S, et al. The rs2294918 E434K variant modulates patatin-like phospholipase
domain-containing 3 expression and liver damage. Hepatology. 2016; 63:787–98. https://doi.org/10.1002/hep.28370 PMID:26605757

17. Chung GE, Lee Y, Yim JY, Choe EK, Kwak MS, Yang JI, Park B, Lee JE, Kim JA, Kim JS. Genetic Polymorphisms of PNPLA3 and SAMM50 Are Associated with Nonalcoholic Fatty Liver Disease in a Korean Population. Gut Liver. 2018; 12:316–23. https://doi.org/10.5009/gnl17306 PMID:29271184

18. Petersen KF, Dufour S, Hariri A, Nelson-Williams C, Foo JN, Zhang XM, Dzurra J, Lifton RP, Shulman GI. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med. 2010; 362:1082–9. https://doi.org/10.1056/NEJMoA0907295 PMID:20335584

19. Sentinelli F, Romeo S, Maglio C, Incani M, Burza MA, Scano F, Coccia F, Cossu E, Leonetti F, Baroni MG. Lack of effect of apolipoprotein C3 polymorphisms on indices of liver steatosis, lipid profile and insulin resistance in obese Southern Europeans. Lipids Health Dis. 2011; 10:93. https://doi.org/10.1186/1476-511X-10-93 PMID:21663607

20. Fan JG, Jia JD, Li YM, Wang BY, Lu LG, Shi JP, Chan LY, and Chinese Association for the Study of Liver Disease. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010: (published in Chinese on Chinese Journal of Hepatology 2010; 18:163-166). J Dig Dis. 2011; 12:38–44. https://doi.org/10.1111/j.1751-2980.2010.00476.x PMID:21276207

21. Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL, McCarthy S, McVean GA, Abecasis GR, and 1000 Genomes Project Consortium. A global reference for human genetic variation. Nature. 2015; 526:68–74. https://doi.org/10.1038/nature15393 PMID:26432245

22. Anderson CA, Pettersson FH, Clarke GM, Cardon LR, Morris AP, Zondervan KT. Data quality control in genetic case-control association studies. Nat Protoc. 2010; 5:1564–73. https://doi.org/10.1038/nprot.2010.116 PMID:21085122

23. Agius L. Targeting hepatic glucokinase in type 2 diabetes: weighing the benefits and risks. Diabetes. 2009; 58:18–20. https://doi.org/10.2337/db08-1470 PMID:19114725

24. Samuel VT, Shulman GI. Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases. Cell Metab. 2018; 27:22–41. https://doi.org/10.1016/j.cmet.2017.08.002 PMID:28867301

25. Pusec CM, De Jesus A, Khan MW, Terry AR, Ludvik AE, Xu K, Giancola N, Pervai H, Davius Smith E, Ding X, Harrison S, Chandel NS, Becker TC, et al. Hepatic HKDC1 Expression Contributes to Liver Metabolism. Endocrinology. 2019; 160:313–30. https://doi.org/10.1210/en.2018-00887 PMID:30517626

26. Grimsby J, Coffey JW, Dvorozniak MT, Magram J, Li G, Matschinsky FM, Shiotani C, Kaur S, Magnuson MA, Grippio JF. Characterization of glucokinase regulatory protein-deficient mice. J Biol Chem. 2000; 275:7826–31. https://doi.org/10.1074/jbc.275.11.7826 PMID:10713097

27. Santoro N, Zhang CK, Zhao H, Pakstis AJ, Kim G, Kursawe R, Dykas DJ, Bale AE, Giannini C, Pierpont B, Shaw MM, Groop L, Caprio S. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology. 2012; 55:781–9. https://doi.org/10.1002/hep.24806 PMID:22105854

28. Errazuriz J, Dube S, Slama M, Visentin R, Nayar S, O’Connor H, Cobelli C, Das SK, Basu A, Kremers WK, Port J, Basu R. Randomized Controlled Trial of a MUFA or Fiber-Rich Diet on Hepatic Fat in Prediabetes. J Clin Endocrinol Metab. 2017; 102:1765–74. https://doi.org/10.1210/jc.2016-3722 PMID:28323952

29. Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD, Gudnason V, Eiriksdottir G, Garcia ME, Launer LJ, Nalls MA, Clark JM, Mitchell BD, et al, and NASH CRN, and GIANT Consortium, and MAGIC Investigators, and GOLD Consortium. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011; 7:e1001324. https://doi.org/10.1371/journal.pgen.1001324 PMID:21423719

30. Wang X, Liu Z, Wang K, Wang Z, Sun X, Zhong L, Deng G, Song G, Sun B, Peng Z, Liu W. Additive Effects of the Risk Alleles of PNPLA3 and TM6SF2 on Non-alcoholic Fatty Liver Disease (NAFLD) in a Chinese Population. Front Genet. 2016; 7:140. https://doi.org/10.3389/fgene.2016.00140 PMID:27532011

31. Yang H, Chen G, Song C, Li D, Ma Q, Chen G, Li X. A novel index including SNPs for the screening of nonalcoholic fatty liver disease among elderly Chinese: A
32. Yang Z, Wen J, Tao X, Lu B, Du Y, Wang M, Wang X, Zhang W, Gong W, Ling C, Wu S, Hu R. Genetic variation in the GCKR gene is associated with non-alcoholic fatty liver disease in Chinese people. Mol Biol Rep. 2011; 38:1145–50. 
https://doi.org/10.1007/s11033-010-0212-1 PMID:20625834

33. Orho-Melander M, Melander O, Guiducci C, Perez-Martinez P, Corella D, Roos C, Tewhey R, Rieder MJ, Hall J, Abecasis G, Tai ES, Welch C, Arnett DK, et al. Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes. 2008; 57:3112–21. 
https://doi.org/10.2337/db08-0516 PMID:18678614

34. Li H, Xu R, Peng X, Wang Y, Wang T. Association of glucokinase regulatory protein polymorphism with type 2 diabetes and fasting plasma glucose: a meta-analysis. Mol Biol Rep. 2013; 40:3935–42. 
https://doi.org/10.1007/s11033-012-2470-6 PMID:23307301

35. Oh SW, Lee JE, Shin E, Kwon H, Choe EK, Choi SY, Rhee H, Choi SH. Genome-wide association study of metabolic syndrome in Korean populations. PLoS One. 2020; 15:e0227357. 
https://doi.org/10.1371/journal.pone.0227357 PMID:31910446

36. Beer NL, Tribble ND, McCulloch LJ, Roos C, Johnson PR, Orho-Melander M, Gloyn AL. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet. 2009; 18:4081–8. 
https://doi.org/10.1093/hmg/ddp357 PMID:19643913

37. Pacifico L, Bonci E, Andreoli G, Romaggioli S, Di Miscio R, Lombardò CV, Chiesa C. Association of serum triglyceride-to-HDL cholesterol ratio with carotid artery intima-media thickness, insulin resistance and nonalcoholic fatty liver disease in children and adolescents. Nutr Metab Cardiovasc Dis. 2014; 24:737–43. 
https://doi.org/10.1016/j.numecd.2014.01.010 PMID:24656140

38. Nichols PH, Pan Y, May B, Pavlicova M, Rausch JC, Mencin AA, Thaker VV. Effect of TSH on Non-Alcoholic Fatty Liver Disease (NAFLD) independent of obesity in children of predominantly Hispanic/Latino ancestry by causal mediation analysis. PLoS One. 2020; 15:e0234985. 
https://doi.org/10.1371/journal.pone.0234985 PMID:32569304

39. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, Clark JM. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011; 54:1082–90. 
https://doi.org/10.1002/hep.24452 PMID:21618575